Minoxidil (MNX), like several other vasoactive drugs, causes cardiovascular toxicity in dogs by undetermined mechanisms. We studied the mechanism of cardiovascular toxicity of MNX [an adenosine triphosphate (ATP)-sensitive potassium channel opener] by blocking its pharmacologic effects with glyburide (an ATPsensitive potassium channel blocker) in groups of 5 female beagle dogs treated orally for 2 days with 1.0 mg/ kg/day of MNX alone or with glyburide given in 5 or 6 divided doses of 300 mg/kg at 2 hr before and after each dose of MNX and at 3-6-hr intervals thereafter. A third group of 5 dogs received glyburide alone in the same dosing regimen as in the combination group. Mean arterial pressure (MAP), heart rate (HR), the pharmacokinetics of MNX, and gross and microscopic changes in the heart were evaluated. Glyburide did not influence the pharmacokinetics of MNX but prevented or markedly attenuated the MNX-induced cardiovascular lesions (right atrial hemorrhagic lesions, subendocardial necrosis, or coronary arteritis) occurred in dogs whose MNX-induced hemodynamic effects were effectively blocked by glyburide. In conclusion, the cardiovascular toxicity of MNX in dogs is not caused by a direct toxic effect of MNX on the heart but apparently is related to the exaggerated pharmacologic/profound hemodynamic effects it elicits in the dog.
INTRODUCTION
The cardiovascular toxicity of minoxidil (MNX; pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide), an adenosine triphosphate (ATP~sensitive potassium channel opener vasodilator (7, 23) used in the treatment of hypertension (Loniten &reg; Tablets) and androgenic alopecia (Rogaine @ 2% Solution), has been characterized in the dog (4, 13, 29) . MNX, like several other cardioactive drugs that have comparable effects on the heart (coronary vasodilation and tachycardia), causes subendocardial and papillary muscle necrosis, coronary arterial medial hemorrhage and necrosis, and right atrial hemorrhages in the dog (3, 4, 6, 13, 29) . The mechanisms of the cardiovascular toxicity of MNX in the dog are undetermined but are generally regarded to be related to the exaggerated pharmacologic/hemodynamic ef-fects of this class of drugs rather than to a direct toxicity of the drugs on the heart (3, 6, 29) . Modulation of the sympathetic nervous system by surgical or chemical sympathectomy or by adaptation of the sympathetic nervous system to the effects of MNX by gradually increasing the dose of MNX did not have a significant impact on the incidence of these lesions (29) . The contention that the cardiovascular lesions associated with MNX or other vasculo/cardioactive drugs are caused by exaggerated pharmacologic effects of these drugs continues to be challenged because these assertions are based on the association of hemodynamic effects and lesions seen with this class of drugs rather than on direct experimental data. The incidence of MNX-induced myocardial subendocardial necrosis was decreased in dogs pretreated with furosemide for 11 days (12) , suggesting that this lesion may be related to the pharmacologic effects of the drug. If the cardiovascular lesions seen with MNX are indeed caused by exaggerated pharmacologic effects, then attenuation or prevention of the these effects with a pharmacologic blocker would be expected to modulate or prevent the lesions. The prevention of medial hem-orrhage and necrosis of the splanchnic arteries of rats caused by fenoldapam, a dopamine receptor agonist vasodilator, with a dopamine receptor antagonist (20) suggested that pharmacologic blockade may indeed be used to determine the basis of toxicologic findings in dogs treated with MNX. Glibenclamide (glyburide), a sulfonylurea antidiabetic drug, a specific ATP-sensitive potassium channel blocker (1), has been shown to prevent the pharmacologic effects of MNX sulfate, the active moiety of MNX (22) , and other ATP-sensitive potassium channel openers in vitro and in vivo (8, 14, 25, 35, 38, 39) . Although the hypotensive effects of cromakalim and pinacidil have been successfully blocked by glibenclamide in vivo (8, 34, 35) , the effect of such a blocking on the cardiovascular toxicity of these ATP-sensitive potassium channel openers has not been determined. In this study, we tested the hypothesis that MNX-induced cardiovascular lesions in dogs are related to the exaggerated pharmacologic effects of the drug by blocking the pharmacologic effects of MNX with glyburide.
MATERIALS AND METHODS
Chemicals. MNX and glyburide ( Fig. 1 Euthanasia and Tissue Processing. At the end of the experiment, dogs were euthanatized by iv injection of Socumb euthanasia solution (The Butler Co., Columbus, OH), exsanguinated, and examined for any gross lesions. Selected tissues were fixed in 10% formalin. Samples from the left and right atria with their respective coronary arteries, left and right auricles, right ventricular wall including its papillary muscle, dorsal and ventral papillary muscles of the left ventricle, the mid-and apical portions of the left ventricle, and interventricular septum were embedded in paraffin, sectioned at 6,4m, routinely processed, and stained with hematoxylin-phloxine-eosin. The dorsal and ventral papillary muscles of the left ventricle and selected cardiac sections were also stained with Mason's trichrome methods.
Statistical
Analysis. An initial analysis using repeated-measures analysis of covariance, using pretest values as covariates, was conducted on HR and MAP. If the time to treatment interaction was not significant, then an overall test for treatment effects was made. For significant treatment effects, pairwise comparisons were conducted. If the interactions were significant, treatment group differences at each time point were analyzed using a 1-way analysis of covariance on raw data in conjunction with an analysis of covariance on ranks of data. If the treatment effect bSignificantly different from glyburide plus MNX, p < 0.05. was significant, pairwise comparisons were made using the least significant difference method. The differences in C~ax. T malO AUC~t, AUC~, and t,/, between the group treated with MNX alone and that treated in combination with glyburide were evaluated as a function of treatment by means of a t-test.
RESULTS

Clinical, Hematological, and Serum Chemical Changes
Exaggerated carotid pulsation was detected digitally and in some cases visually in all dogs treated with MNX alone and in 1 dog (# 15) treated with MNX plus glyburide. The feces in dogs treated with glyburide alone or with MNX were discolored white. There were no adverse effects on body weight or hematology. Serum glucose concentration was decreased in all dogs treated with glyburide alone or with MNX ( Fig. 2 ). Serum sodium concentration was slightly decreased in dogs treated with MNX alone.
HR
Covariant adjusted group mean HR in dogs treated with glyburide or MNX alone, or with both drugs, are summarized in Fig. 3 . There was a significant increase in covariate adjusted group mean HR in groups treated with MNX alone compared to groups treated with glyburide alone or with MNX. There was no difference in HR between groups treated with glyburide alone and those treated with glyburide plus MNX. Glyburide, under the conditions of this experiment, did not completely block the MNX- -Individual HR (beats/min) in dogs treated orally with 1,500-1,800 mg/kg/day of glyburide given in 5 or 6 equally divided doses plus 1.0 mg/kg/day of MNX for 2 days. induced tachycardia, but it markedly attenuated it. HR in the group treated with MNX plus glyburide was significantly lower than in the group treated with MNX alone but was significantly higher than in the group treated with glyburide alone.
The HR in the MNX-treated dogs increased sharply within the first hour of treatment, reached peak levels (mean value of 198-225 beats/min) at 4-8 hr after the first dose, and remained high (over 17 5 beats/min) during the course of the study. HR in 3 of the 5 dogs treated with glyburide plus MNX remained close to the pretest values throughout the study (Fig. 4 ). In I combination dog (# 15), HR was moderately increased at 4-20 hr after the first dose of MNX but remained at pretest levels during the second day of the study. HR in another combination dog (# 14) started to increase at 2 hr after the first dose of MNX and remained markedly increased through the second day of the study. An unscheduled glyburide dose of 300 mg/kg at 11.5 hr after the first dose of MNX did not have much impact on the increased HR in this dog.
MAP
Covariate-adjusted MAP in dogs treated with glyburide or MNX alone, or the combination of the 2 drugs is shown in Fig. 5 . There was a significant decrease in MAP in groups treated with MNX alone when compared to groups treated with glyburide alone or glyburide plus MNX. The MAP in the group treated with MNX alone was decreased by over 20 mmHg and remained low throughout the duration of the study. Unlike HR, MAP in the glyburide group was not significantly different from the combination group. Glyburide prevented the MNX-induced hypotension in all but I dog (# 15) , in which hypotension between 4 and 8 hr after the first dose of MNX was as marked as that seen in dogs treated with MNX alone (Fig. 6) . 
MNX Serum Concentration and Pharmacokinetics
The logarithmic mean MNX serum concentration in dogs treated with MNX with or without glyburide is presented in Fig. 7 . The mean pharmacokinetic parameters with the statistical comparison between the 2 treatment groups are summarized in Table I. MNX was rapidly absorbed after oral administration regardless of whether it was administered alone or with glyburide. In both groups, peak serum concentrations were achieved within 2 hr after dosing.
There was no significant difference in the serum concentration of MNX or any of the pharmacokinetic parameters (C~x. T_,,, AUC, and t,,2) between dogs treated with MNX alone and dogs treated with MNX plus glyburide, indicating that the high dose of glyburide did not alter the absorption and pharmacokinetics of MNX.
Fm. 6. -Individual MAP (mmHg) in dogs treated orally with 1,500-1,800 mg~kglday of glyburide given in 5 or 6 equally divided doses plus 1.0 mg'kg&dquo;day of MNX for 2 days. 
Necropsy Observations
All MNX-treated dogs had focal to multifocal dark red discoloration (hemorrhage) over the epicardium of the right atrium or the endocardium of the left ventricle or left papillary muscle. One dog each treated with MNX alone or in combination with glyburide (# 15) showed focal pale discoloration in the endocardium of the left ventricle. None of the dogs treated with glyburide alone showed any gross cardiac lesions. Small flecks of white pasty material (presumably bulk drug) lined the gastrointestinal tract of dogs that were given glyburide alone or with MNX. Incidental gross changes noted included a hemorrhagic area over the hepatic capsule, an aplastic right kidney, and a localized edema in the mesentery in I dog treated with glyburide plus MNX.
Microscopic Findings
Treatment-related microscopic findings in the heart of dogs treated with MNX, glyburide, or MNX plus glyburide are summarized in Table II . All dogs treated with MNX alone and 1 combination dog (# 15) had right atrial epicardial hemorrhage/inflammation of varying intensity. These lesions were characterized by the expansion of the subepicardium of the atrium/auricle with edema, extravasated red blood cells, and aggregates of inflammatory cells comprised ofneutrophils and histiocytes (macrophages).
All 5 dogs treated with MNX alone had arterial medial hemorrhage/necrosis in some of the branches of the coronary arteries. Coronary arterial lesions were more consistent and invariably more extensive in the right than in the left atrial branches of the coronary arteries. Coronary arterial lesions were rare and minimal in the ventricular branches of the coronary arteries. Vascular lesions were usually seen in the medium-sized muscular arteries located in the coronary groove or in the loose connective tissue of the subepicardium of the atria. Arterial lesions, when present in the ventricles, were confined to the epicardial branches of the descending coronary arteries. None of the larger conductance vessels in the atria or ventricles were affected.
The ventral or dorsal left papillary muscle in 4 of the 5 MNX-treated dogs showed focal or multifocal minimal localized areas of necrosis characterized by acute myofiber degeneration/necrosis with contraction bands. One of the dogs treated with MNX also had focal subendocardial necrosis of the left ventricle. Acute multifocal necrosis located toward the epicardial surface of the left ventricle was noted in another MNX-treated dog. Dog # 15, treated with MNX and glyburide, had focal areas of necrosis in the papillary muscle and in the subendocardium of the left and right ventricles.
None of the dogs treated with glyburide alone showed any cardiovascular lesions considered to be related to treatment. A focal minimal subacute epicarditis or a relatively thick epicardial fibromyxomatous deposit in the right atrium, changes considered to be incidental, were noted in 1 dog treated with glyburide. Unlike in the MNX-treated dogs, mast cells and lymphocytes formed the primary inflammatory cellular component of the focal epicardial lesion. Atrial epicardial fronds, a common spontaneous incidental lesion in the beagle dog (28) , was noted in some of the dogs in all treatment groups.
DISCUSSION
Dogs treated with 1.0 mg/kg/day of MNX orally for 2 days had exaggerated carotid pulsation (indi-TABLE L-Summary of statistical comparison of selected pharmacokinetic parameters in dogs treated orally with MNX alone or MNX plus glyburide for 2 days. a 1 mg/kglday of MNX. b 1 mg/kg/day of MNX; 1,$00 (day 1) or 1,~00 (day 2) mg/kg of glyburide. TABLE II.-Summary of treatment-related microscopic findings in the heart of dogs treated orally with glyburide, MNX, or a combination of the 2 drugs.&dquo; a Glyburide was given in 6 and 5 equally divided doses of 300 mg/kg on days 1 and 2, respectively, 2 hr before 1.0 mg/kg/day of MNX, 2 hr after MNX, and every 3-6 hr thereafter. b All findings in the combination group were in 1 dog (# 15). rect evidence of increased cardiac output), decreased MAP, increased HR, and cardiovascular toxicity characterized by right atrial hemorrhages, subendocardial (papillary muscle) necrosis, and coronary arterial medial hemorrhage/necrosis, changes similar to those reported previously (3, 6, 13, 29) . The presence of myocardial necrosis on the epicardial side of the left ventricle in one of the MNX-treated dogs in this study is not consistent with the generally held view that myocardial necrosis in dogs treated with MNX and other vasodilators is confined to the subendocardium (3, 6, 9, 12, 13, 29) , the region of the heart vulnerable to ischemic necrosis (15) . Dog # 14, treated with MNX and glyburide, despite marked and sustained tachycardia, did not develop cardiovascular lesions, suggesting that tachycardia unattended by hypotension may not be a sufficient insult to cause cardiovascular lesions. This is not surprising considering that exercise-induced tachycardia, regardless of its intensity, does not cause subendocardial necrosis. The vasomotor control mechanisms of vessels that regulate transmural myocardial perfusion are not paralyzed during exercise-related tachycardia as they are during vasodilator-induced tachycardia (2) .
The absence of cardiovascular lesions in dogs treated with MNX and glyburide (except # 15), despite comparable serum concentrations of MNX in this group and the group treated with MNX alone, indicated that the cardiotoxicity of MNX was not caused by a direct toxic effect of MNX on the heart. Similar MNX serum concentrations in groups treated with MNX alone or with MNX plus glyburide, however, do not mean that MNX had opened the vascular potassium channels in the combination group; it could be argued that the mere presence of glyburide may have prevented the opening of the potassium channels by MNX. This possibility was considered unlikely because of the emergence of tachycardia after the effect of glyburide had waned (determined in preliminary unpublished data). MNX must have remained bound to its potassium channel receptor to show its effect (tachycardia) without an additional dose of MNX. This observation is consistent with the report that MNX sulfate binds covalently and irreversibly to the potassium channel proteins (24, 26) . It has also been shown that the antagonism of MNX sulfate by glyburide is noncompetitive, as opposed to the competitive interaction between other potassium channel openers (e.g., cromakalim) and glyburide ( 10, 24, 32, 38) .
High doses of glyburide, a sulfonylurea, blocked or markedly attenuated the hypotension and tachycardia (indirect indicators of vasodilation) associated with MNX treatment. Sulfonylureas, by blocking the ATP-sensitive potassium channels (I), prevent the vasorelaxant and hypotensive effects of ATP-sensitive potassium channel openers in vitro and in vivo (8, 14, 25, 32-35, 38, 39) . Although glyburide strikingly attenuated the MNX-induced hemodynamic effects (indirect evidence of vasodilation) in the group treated with MNX and glyburide, it did not completely block the effects of MNX on the vessels, as indicated by the slight increase in HR in the combination group. The basis of the incomplete blockage of the pharmacologic effects of MNX by glyburide was not determined. It also is not known why tachycardia occurred in # 14 despite a complete prevention of the hypotensive effects of MNX. There is no evidence indicating that MNX activates any other plasmalemma channel besides the ATP-sensitive potassium channel in smooth muscle cells. MNX has, however, been shown to shorten the cardiac action potential not only through the ATP-sensitive potassium channel but also through suppressing L-type Ca-+ channel currents (11) . It has also been reported that other ATP-sensitive potassium channel openers (cromakalim and pinacidil) open the Ca++-gated channel and the Ca++-dependent potassium channel, respectively (18, 27) . Several K+-channel openers at high doses have been reported to shorten ventricular action potential (19, 30, 33) .
The incomplete blockade of the pharmacologic effects of MNX by glyburide in this study, regardless of its mechanism, did not compromise the objective of the study; instead, it strengthened the association between hemodynamic effects and cardiotoxicity of MNX in the dog by providing additional positive control dogs (# 14 and # 15). The absence of cardiovascular toxicity in the combination group, despite a modest tachycardia, indicated that the pharmacologic effects of MNX would have to be profound to cause cardiotoxicity in the dog. This study also showed that MNX-induced tachycardia, unattended by hypotension, did not seem to cause cardiac lesions (#14) and hypotension and tachycardia did not have to be sustained for a long period of time to cause subendocardial ischemic necrosis (#15). However, a dose-response study may be needed to confirm that hypotension is the most critical quantifiable variable in the genesis of MNX-induced cardiac lesions.
The actual mechanisms of the various cardiovascular lesions induced by MNX are unknown but do not appear to have the same pathogenetic mechanisms. A proposed pathogenesis of the various lesions caused by MNX and other vasodilators is summarized in Fig. 8 . The underlying fundamental process for all 3 types of lesions in dogs treated with MNX (right atrial hemorrhagic lesion, subendocar-dial/papillary muscle necrosis, and coronary vascular medial hemorrhage/necrosis) is vasodilation. The presence of subendocardial necrosis in dog # 15 that had hypotension and tachycardia, conditions that predispose to hypoxia, was consistent with the generally held view that this lesion was probably caused by ischemia. Medial hemorrhage and necrosis of the muscular branches of the coronary arteries were most likely related to a change in arterial wall tension, a factor known to cause arterial medial lesions (17, 21, 31 ) . The right atrial hemorrhagic lesions, unlike the subendocardial necrosis, appeared to be a hyperperfusion phenomenon that would be expected to occur with an 8-fold increase in coronary blood flow after an oral dose of 1.0 mg/kg MNX (16) . The selective distribution of MNX-induced hemorrhage in the right atrium in the dog and left atrium in the pig (37) remains an enigma. The difference in the pattern of coronary circulation between dogs and pigs (5) may have a bearing on the species-specific localization of atrial lesions in dogs and pigs treated with MNX. The right atrium of the dog seems prone to hemorrhagic lesions. Dogs exposed to single large doses of radiation developed a hemorrhagic lesion in the heart confined to the right atrium (36) . In summary, dogs treated with 1.0 mg/kg/day of MNX orally for 2 days showed exaggerated carotid pulsation, hypotension, tachycardia, and cardiotoxicity. Glyburide at 1,500 or 1,800 mg/kg/day in 5 or 6 equally divided oral doses was well tolerated, did not influence the absorption or pharmacokinetics of MNX, and prevented or attenuated MNX-induced hemodynamic responses and cardiotoxicity in the dog. Cardiovascular toxicity occurred only if MNX-induced hypotension and tachycardia were not effectively blocked or attenuated by glyburide, suggesting that the cardiovascular toxicity of MNX in dogs is apparently caused by the exaggerated pharmacologic effects rather than direct toxicity of the drug to the heart.
